Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37306
Title: | The MADIT-ICD benefit score helps to select implantable cardioverter-defibrillator candidates in cardiac resynchronization therapy | Authors: | DAUW, Jeroen MARTENS, Pieter NIJST, Petra MEEKERS, Evelyne DEFERM, Sebastien GRUWEZ, Henri Rivero-Ayerza, Maximo Van Herendael, Hugo PISON, Laurent NUYENS, Dieter DUPONT, Matthias MULLENS, Wilfried |
Issue Date: | 2022 | Publisher: | OXFORD UNIV PRESS | Source: | EUROPACE, MAR 2022 | Status: | Early view | Abstract: | Aims The aim of this study is to evaluate whether the MADIT-ICD benefit score can predict who benefits most from the addition of implantable cardioverter-defibrillator (ICD) to cardiac resynchronization therapy (CRT) in real-world patients with heart failure with reduced ejection fraction (HFrEF) and to compare this with selection according to a multidisciplinary expert centre approach. Methods and results Consecutive HFrEF patients who received a CRT for a guideline indication at a tertiary care hospital (Ziekenhuis Oost-Limburg, Genk, Belgium) between October 2008 and September 2016, were retrospectively evaluated. The MADIT-ICD benefit groups (low, intermediate, and high) were compared with the current multidisciplinary expert centre approach. Endpoints were (i) sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and (ii) non-arrhythmic mortality. Of the 475 included patients, 165 (34.7%) were in the lowest, 220 (46.3%) in the intermediate, and 90 (19.0%) in the highest benefit group. After a median follow-up of 34 months, VT/VF occurred in 3 (1.8%) patients in the lowest, 9 (4.1%) in the intermediate, and 13 (14.4%) in the highest benefit group (P < 0.001). Vice versa, non-arrhythmic death occurred in 32 (19.4%) in the lowest, 32 (14.6%) in the intermediate, and 3 (3.3%) in the highest benefit group (P = 0.002). The predictive power for ICD benefit was comparable between expert multidisciplinary judgement and the MADIT-ICD benefit score: Uno's C-statistic 0.69 vs. 0.69 (P = 0.936) for VT/VF and 0.62 vs. 0.60 (P = 0.790) for non-arrhythmic mortality. Conclusion The MADIT-ICD benefit score can identify who benefits most from CRT-D and is comparable with multidisciplinary judgement in a CRT expert centre. | Notes: | Mullens, W (corresponding author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. wilfried.mullens@zol.be |
Keywords: | Heart failure; Implantable cardioverter-defibrillator; Cardiac;resynchronization therapy; Patient selection; MADIT-ICD benefit score | Document URI: | http://hdl.handle.net/1942/37306 | ISSN: | 1099-5129 | e-ISSN: | 1532-2092 | DOI: | 10.1093/europace/euac039 | ISI #: | WOS:000784737700001 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Show full item record
WEB OF SCIENCETM
Citations
4
checked on Oct 14, 2024
Page view(s)
92
checked on Jun 21, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.